Avacta Group PLC's (LON:AVCT) Alastair Smith tells Proactive London's Andrew Scott they've selected the cancer drug candidate they'll be taking into first-in-human clinical trials.
It's an important step for the company as it means they remain on track to submit an investigational new drug/clinical trial application by the end of next year.